Abstract
A series of 6-phenyl-3(2H)-pyridazinones with a diverse range of substituents in the 5-position have been prepared and evaluated in the search for new antiplatelet agents. A significant dependence of the substituent on the inhibitory effect has been observed. The pharmacological study of these compounds confirms that modification of the chemical group at position 5 of the 6-phenyl-3(2H)-pyridazinone system influences both variations in the antiplatelet activity and the mechanism of action.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
3',5'-Cyclic-AMP Phosphodiesterases
-
Animals
-
Blood Platelets / drug effects
-
Blood Platelets / metabolism
-
Calcium / metabolism
-
Cyclic Nucleotide Phosphodiesterases, Type 3
-
Cytosol / chemistry
-
Dose-Response Relationship, Drug
-
Guinea Pigs
-
Humans
-
Inhibitory Concentration 50
-
Kinetics
-
Phosphodiesterase Inhibitors / chemical synthesis
-
Phosphodiesterase Inhibitors / pharmacology
-
Phosphorylation
-
Platelet Aggregation Inhibitors / chemical synthesis*
-
Platelet Aggregation Inhibitors / pharmacology
-
Pyridazines / chemical synthesis*
-
Pyridazines / pharmacology
-
Structure-Activity Relationship
Substances
-
Phosphodiesterase Inhibitors
-
Platelet Aggregation Inhibitors
-
Pyridazines
-
3',5'-Cyclic-AMP Phosphodiesterases
-
Cyclic Nucleotide Phosphodiesterases, Type 3
-
Calcium